The challenge of this project is to improve the performance of our biosensors, to improve their range and effectiveness for detecting different biomarkers, keeping them label-free and providing quantitative information through a simple and low-cost measurement system.

The objectives pursued by this project are two. First, validate the potential of the consortium’s proprietary antibodies in early diagnosis in Alzheimer’s patients. Second, obtain a first proof of concept that confirms the viability and efficacy of an immunotherapy based on those antibodies.

In this project we are going to develop a new assay methodology for the early detection of AIDS through the detection of the p24 protein in blood, which appears a few days after the patient has been infected. Using our technology, we will improve the limit of detection in the recognition of target molecules.

BiOD is the lead partner for the read-out hardware and fully responsible for coordinating the commercial exploitation of the AllerScreening platform.